Clinical Trial Update: Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities [Phase 2]

View source ↗

Summary

Phase 2 trial update on EGFR-TKI treatment for residual lesions in patients with multiple synchronous ground-glass opacities (multiple primary lung cancers).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ground-glass Opacities of the Lung
• Multiple Primary Lung Cancers

Drugs mentioned

• EGFR-TKI (EGFR tyrosine kinase inhibitor)

Snippet

Sponsor: Ruijin Hospital | Conditions: Multiple Primary Lung Cancers | Phase 2 | Status: UNKNOWN